But, at least in the
venture capital world,
funding for companies focused on tackling heart disease, respiratory disease, and other mass population conditions — i.e., those that afflict millions upon millions of people — has
dropped sharply in the last decade.
It attracted investment from healthcare industry officials and
venture capital funds, raising $ 21.2 million, according to database ICO
Drops.